Rabbit Polyclonal UGT1A9 antibody. Suitable for WB and reacts with Human samples. Cited in 3 publications. Immunogen corresponding to Recombinant Fragment Protein within Human UDP-glucuronosyltransferase 1A9 aa 250 to C-terminus.
Images
Publications
Filter by
- Molecules (Basel, Switzerland) 25:2020Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity.Applications:Unspecified applicationReactive species:Unspecified reactive speciesJunichi Okada et. al.PubMed 31979355
- Frontiers in pharmacology 10:11112019Oleanolic Acid and Ursolic Acid Induce UGT1A1 Expression in HepG2 Cells by Activating PXR Rather Than CAR.Applications:Unspecified applicationReactive species:Unspecified reactive speciesNa Yao et. al.PubMed 31611795
- Molecular cancer research : MCR 12:1042-542014FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.Applications:Unspecified applicationReactive species:Unspecified reactive speciesJaime Acquaviva et. al.PubMed 24784839
Key facts
- Isotype
- IgG
- Host species
- Rabbit
- Storage buffer
pH: 7
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 20% Glycerol (glycerin, glycerine), 1.21% Tris, 0.75% Glycine- Form
- Liquid
- Clonality
- Polyclonal
Immunogen
- Recombinant Fragment Protein within Human UDP-glucuronosyltransferase 1A9 aa 250 to C-terminus. The exact immunogen used to generate this antibody is proprietary information. Database link O60656
Reactivity data
Select an application| WB | |
|---|---|
| Human | Tested |
| Mouse | Predicted |
| Monkey | Predicted |
WB
TestedTested
| Species | Dilution info | Notes |
|---|---|---|
Species Human | Dilution info 1/500.00000 - 1/3000.00000 | Notes - |
PredictedPredicted
| Species | Dilution info | Notes |
|---|---|---|
Species Mouse, Monkey | Dilution info - | Notes - |
Associated Products
Select an associated product type
2 products for Alternative Product
Target data
Function
Isoform 1. UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile (PubMed:12181437, PubMed:15470161, PubMed:15472229, PubMed:18004212, PubMed:18052087, PubMed:18674515, PubMed:19545173). Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds (PubMed:12181437, PubMed:18004212). Catalyzes the glucuronidation of endogenous estrogen hormones such as estradiol and estrone (PubMed:15472229). Also catalyzes the glucuronidation of the isoflavones genistein, daidzein, glycitein, formononetin, biochanin A and prunetin, which are phytoestrogens with anticancer and cardiovascular properties (PubMed:18052087, PubMed:19545173). Involved in the glucuronidation of the AGTR1 angiotensin receptor antagonist caderastan, a drug which can inhibit the effect of angiotensin II (PubMed:18674515). Involved in the biotransformation of 7-ethyl-10-hydroxycamptothecin (SN-38), the pharmacologically active metabolite of the anticancer drug irinotecan (PubMed:12181437, PubMed:20610558). Also metabolizes mycophenolate, an immunosuppressive agent (PubMed:15470161, PubMed:18004212). Isoform 2. Lacks UGT glucuronidation activity but acts as a negative regulator of isoform 1.
Alternative names
GNT1, UGT1, UGT1A9, UDP-glucuronosyltransferase 1A9, UDP-glucuronosyltransferase 1-9, UDP-glucuronosyltransferase 1-I, lugP4, UDPGT 1-9, UGT1*9, UGT1-09, UGT1.9, UGT-1I, UGT1I
Recommended products
Rabbit Polyclonal UGT1A9 antibody. Suitable for WB and reacts with Human samples. Cited in 3 publications. Immunogen corresponding to Recombinant Fragment Protein within Human UDP-glucuronosyltransferase 1A9 aa 250 to C-terminus.
Key facts
- Isotype
- IgG
- Host species
- Rabbit
- Storage buffer
pH: 7
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 20% Glycerol (glycerin, glycerine), 1.21% Tris, 0.75% Glycine- Form
- Liquid
- Clonality
- Polyclonal
- Immunogen
- Recombinant Fragment Protein within Human UDP-glucuronosyltransferase 1A9 aa 250 to C-terminus. The exact immunogen used to generate this antibody is proprietary information. Database link O60656
- Purification technique
- Affinity purification Immunogen
- Concentration
Storage
- Shipped at conditions
- Blue Ice
- Appropriate short-term storage conditions
- +4°C
- Appropriate long-term storage conditions
- -20°C
- Aliquoting information
- Upon delivery aliquot
- Storage information
- Avoid freeze / thaw cycle
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
UGT1A9 also known as UDP-glucuronosyltransferase 1-9 mechanistically catalyzes the glucuronidation of a variety of substrates including pharmaceuticals endogenous compounds and xenobiotics. It belongs to the UGT1A family with an approximate mass of 56 kDa. UGT1A9 is mainly expressed in the liver but it also shows expression in other tissues like the kidney and the small intestine. The enzyme plays an important role in increasing the solubility of drugs aiding their excretion from the body.
- Biological function summary
UGT1A9 is involved in phase II metabolism contributing to the detoxification processes within the liver. It functions by adding glucuronic acid to lipophilic molecules making them more water-soluble. This glucuronidation process is essential for the clearance of bilirubin steroids and various drugs. UGT1A9 exists as a part of a larger enzyme complex that includes other UGT1A family members. Together these enzymes regulate action and metabolism of diverse physiological substances.
- Pathways
The UGT1A9 enzyme contributes significantly to the glucuronidation pathway and assists in the drug metabolism pathway. It shares functional relationships with other UGT1A enzymes like UGT1A1 particularly in the metabolism of bilirubin. In the drug metabolism pathway UGT1A9 interacts with cytochrome P450 enzymes playing an important role in the reduction of drug toxicity and facilitation of drug clearance.
- Associated diseases and disorders
UGT1A9 has been linked to Gilbert's syndrome and drug-induced hepatotoxicity. Mutations or polymorphisms in the UGT1A9 gene can lead to impaired ability of the enzyme to glucuronidate bilirubin potentially contributing to hyperbilirubinemia in Gilbert's syndrome. UGT1A9 also interacts with proteins such as UGT1A1 in the context of drug-induced liver injury affecting the metabolism of certain therapeutic drugs leading to potential toxic buildup.
Product promise
Tested
We have tested this species and application combination and it works. It is covered by our product promise.
Expected
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
Predicted
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
Not recommended
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
1 product image
Western blot - Anti-UGT1A9 antibody (ab96214)
7.5% SDS PAGE
All lanes: Western blot - Anti-UGT1A9 antibody (ab96214) at 1/1000 dilution
All lanes: H1299 whole cell lysate at 30 µg
Predicted band size: 60 kDa
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com